BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11795327)

  • 1. Implications of FDA's proposal to include foreign marketing experience in the over-the-counter drug review process.
    Pinco RG
    Food Drug Law J; 1998; 53(1):105-22. PubMed ID: 11795327
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 4. Additional criteria and procedures for classifying over-the-counter drugs as generally recognized as safe and effective and not misbranded. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(15):3060-76. PubMed ID: 11820251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(27):5942-3. PubMed ID: 11837282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA's response to food, dietary supplement, and cosmetic adverse events.
    Bren L
    FDA Consum; 2003; 37(4):12-3. PubMed ID: 12971342
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs and other product choices.
    Hyman PM; Carvajal R
    Dermatol Ther; 2009; 22(3):216-24. PubMed ID: 19453345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31125-7. PubMed ID: 12001972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 12. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

  • 13. What has been happening with over-the-counter drug regulation.
    Stringer S
    Food Drug Law J; 1998; 53(4):633-41. PubMed ID: 10557581
    [No Abstract]   [Full Text] [Related]  

  • 14. Beyond ephedra. Why the FDA's ban may lead users to look for other weight-loss stimulants.
    Gupta S
    Time; 2004 Jan; 163(2):78. PubMed ID: 14735657
    [No Abstract]   [Full Text] [Related]  

  • 15. Need a new drug?
    Gorman C
    Time; 1995 Jul; 146(5):52. PubMed ID: 10144386
    [No Abstract]   [Full Text] [Related]  

  • 16. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States?
    Gibson JE; Taylor DA
    J Pharmacol Exp Ther; 2005 Sep; 314(3):939-44. PubMed ID: 15833895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teaching the elephant to dance: privatizing the FDA review process.
    Price EC
    Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
    [No Abstract]   [Full Text] [Related]  

  • 18. Surrogate endpoints and FDA's accelerated approval process.
    Fleming TR
    Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Nov; 81(226):84465-77. PubMed ID: 27906534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.